Beta

Belite bio, incBLTE.US Overview

US StockHealthcare
(No presentation for BLTE)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

BLTE AI Insights

BLTE Overall Performance

BLTE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BLTE Recent Performance

-2.66%

Belite bio, inc

-1.10%

Avg of Sector

-0.49%

S&P500

BLTE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check BLTE's Trend

BLTE Key Information

BLTE Valuation Metrics

BLTE Profile

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Price of BLTE

BLTE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BLTE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.94
PE Ratio (TTM)
-
Forward PE
227.27
PS Ratio (TTM)
-
PB Ratio
8.53
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.94
PE Ratio (TTM)
-
Forward PE
227.27
PS Ratio (TTM)
-
PB Ratio
8.53
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is BLTE's latest earnings report released?

    The most recent financial report for Belite bio, inc (BLTE) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BLTE's short-term business performance and financial health. For the latest updates on BLTE's earnings releases, visit this page regularly.

  • How much cash does BLTE have?

    At the end of the period, Belite bio, inc (BLTE) held Total Cash and Cash Equivalents of 157.03M, accounting for 0.56 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BLTE's EPS continuing to grow?

    According to the past four quarterly reports, Belite bio, inc (BLTE)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.72. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What are the PEG ratio and PE ratio of BLTE?

    The latest valuation data shows Belite bio, inc (BLTE) has a Price-To-Earnings (PE) ratio of -52.96 and a Price/Earnings-To-Growth (PEG) ratio of -4.92. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.